A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast CancerJAGIELLO-GRUSZFELD, Agnieszka; TJULANDIN, Sergei; DOBROVOLSKAYA, Natalya et al.Oncology. 2010, Vol 79, Num 1-2, pp 129-135, issn 0030-2414, 7 p.Article

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analysesCAMERON, David; CASEY, Michelle; CHAN, Arlene et al.Breast cancer research and treatment. 2008, Vol 112, Num 3, pp 533-543, issn 0167-6806, 11 p.Article

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic RegimensVALERO, Vicente; FORBES, John; FUMOLEAU, Pierre et al.Journal of clinical oncology. 2011, Vol 29, Num 2, pp 149-156, issn 0732-183X, 8 p.Article

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial TractBELLMUNT, Joaquim; THEODORE, Christine; DELGADO, Prançois-Michel et al.Journal of clinical oncology. 2009, Vol 27, Num 27, pp 4454-4461, issn 0732-183X, 8 p.Article

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma : a randomised, double-blind phase III trial. CommentaryMOTZER, Robert J; BASCH, Ethan; MELICHAR, Bohuslav et al.Lancet (British edition). 2007, Vol 370, Num 9605, issn 0140-6736, 2071-2073, 2103-2111 [12 p.]Article

Lapatinib plus capecitabine for HER2-positive advanced breast cancerGEYER, Charles E; FORSTER, John; SKARLOS, Dimosthenis et al.The New England journal of medicine. 2006, Vol 355, Num 26, pp 2733-2743, issn 0028-4793, 11 p.Article